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Abstract 
Prior to the 1970s and the advent of Rho (D) immune globulin (RIG) for Rh negative women, hemolytic disease 
of the newborn led to morbidity, long-term disabilities, and mortality. Antepartum RIG administration has been 
a standard of practice since 1983. Yet, Rh isoimmunization (sensitization) and its sequelae have not been 
completely eradicated. Rh-related issues remain clinical challenges facing perinatal and neonatal nurses. 
Evidence for the administration of RIG prenatally and during the postpartum period is presented including 
controversies and challenges. Current information about fetal and neonatal care of erythroblastosis fetalis and 
immune hydrops is also presented. 
 
RH isoimmunization is the leading cause of maternal sensitization. 1,2 While there is extensive information on Rh 
isoimmunization in the medical literature, there is limited practical information in the nursing literature. 
Knowledge of the nursing management and prevention of Rh isoimmunization is of interest to perinatal and 
neonatal nurses. However, it can be difficult to maintain competency in this complex body of knowledge 
because Rh isoimmunization is a relatively rare event. Therefore opportunities to apply this information into 
clinical practice are infrequent. 
The purpose of this article is to present nursing management of Rh isoimmunization through the use of case-
based learning. The principles of adult learning suggest that professionals can review existing knowledge and 
apply new knowledge optimally if it is presented in the context of real-life situations. Case-based learning 
provides opportunities for the application of information to clinical practice. 
Under usual circumstances, maternal and fetal circulations remain distinct and separate throughout pregnancy. 
There is however an intimate relationship between the fetal capillary bed and the maternal circulatory system 
with a delicate vascular exchange taking place within the placenta. 3 Alterations in this balanced system can 
create problems for pregnancies. If maternal and fetal blood comingle because of a feto-maternal hemorrhage 
(FMH) with even a small amount of fetal blood entering the maternal system, a maternal-fetal blood 
incompatibility can develop. 
A common and potentially serious type of maternal-fetal blood incompatibility is that of the Rhesus D antigen. 
The Rhesus factor was so named because testing in Rhesus monkeys first identified it. Rh incompatibility can 
occur when the fetus is Rh positive with erythrocytes that contain D antigen but the mother has the absence of 
the D antigen on circulating erythrocytes and is therefore considered Rh negative. 2,4 Specifically, if a FMH occurs 
when an Rh negative mother is carrying an Rh positive fetus, her immune system reacts to the antigen and 
forms an antibody to eliminate it. This process is called Rh isoimmunization, 5 also commonly referred to 
as sensitization. The causative factor leading to Rh isoimmunization is called the sensitizing event. Once 
maternal anti-D antibodies have formed, they cross the placenta, attach to fetal red blood cells (RBCs), and 
hemolyze the fetal RBCs. Since the time of the classic works that described Rh isoimmunization, it has remained 
difficult to predict maternal isoimmunization because each woman's response is individualized and depends on 
several factors, including the type of antigen, the strength of the antigen in stimulating the antibody response, 
the amount of antigen, the maternal immune response, the blood type of the infant, and the gestational age of 
the fetus. 2,6,7 Once sensitized, the immune response worsens with each subsequent incompatible pregnancy. 2 
Approximately 15% of all pregnant women are Rh negative. 2 According to Bowman's classic 
work, 8 approximately 17% of these Rh negative women would become isoimmunized perinatally without 
preventative measures. Of those isoimmunized, 90% of cases would occur at the time of birth and 10% in the 
antepartum period because of FMH. Most of these antepartum FMH occur following the 28th week of 
gestation. 9,10 These sensitizing events are common occurrences in the perinatal cycle, and therefore, the risk of 
Rh sensitization is relatively high if preventive intervention does not occur. If the fetus is Rh positive and no 
preventative measures are taken, 0.7% to 1.8% of Rh negative women may experience prenatal 
isoimmunization. 8Figure 1 depicts the process of isoimmunization. 
 Fig 1. Pathogenesis of Rh hemolytic disease of the newborn. Reprinted with permission from 
reference11. Artist: Dimitri Karemikov. 
 
Antepartum Rho (D) immune globulin (RIG) is protective against the effects of FMH. A small amount of fetal 
blood can enter the maternal circulation most often during the birth process, particularly during operative 
deliveries. FMH may also occur during spontaneous or elective abortion, vaginal bleeding during late pregnancy, 
trauma, antepartum hemorrhage, fetal death, and stillbirth. Invasive procedures, such as amniocentesis, 
chorionic villus sampling, cordocentesis, and fetal manipulation, such as external version and fetal surgery, may 
also lead to maternal exposure to fetal blood. 9,12 However, FMH can occur in the absence of observable trauma, 
risk, or surgery. 1 Most FMHs that occur at any point in pregnancy or during low-risk childbirth involve less than 
0.1 mL of fetal blood entering the maternal circulation. 1 Fortunately, major FMH leading to fetal mortality is a 
rare occurrence. Overall, large FMHs of 30 mL or more occur in 0.1% to 0.7% of cases, but their incidence 
increases with complicated operative cesarean or vaginal births (1.7% to 2.5%) and stillbirths (4.5%). 13 However, 
even a small FMH can lead to negative sequelae when the mother and fetus have incompatible blood types. 
The exact amount of fetal blood necessary to mount an immune reaction is somewhat elusive. Rh 
isoimmunization can occur during a first pregnancy if an FMH occurs and the volume is significant. 10 For 
example, anti-D antibodies develop in Rh negative women in response to exposure to Rh positive blood, with 
the probability of exposure directly related to antigen quantity. 3,14 Further, subsequent individual maternal 
antibody responses can increase in response to smaller subsequent volumes of fetal cells. 15However, some 
women do not respond to a single-dose antigen exposure and other exposed individuals do not become 
immunized even after repeated exposures to the antigen. 4,7 
PATHOPHYSIOLOGY OF HEMOLYTIC DISEASE OF THE NEWBORN 
Hemolytic disease of the newborn (HDN) develops when an Rh negative woman who has experienced Rh 
isoimmunization subsequently becomes pregnant with an Rh positive fetus. The maternal antibodies cross the 
placenta into the fetal circulation and begin to hemolyze fetal erythroblasts. The maternal antibodies are 
detectable unbound in fetal serum and are also absorbed into D positive erythrocytes. 1 The absorbed 
antibodies function as hemolysins, leading to erythroblastosis fetalis. Erythroblastosis fetalis is the accelerated 
destruction of fetal RBCs leading to severe fetal anemia and HDN. Characteristics that are predictive of HDN (as 
shown in Fig 1) include the presence of ascites, edema, polyhydramnios, placental thickness of more than 4 cm, 
pleural and pericordial effusion, dilation of the cardiac chambers, chronic enlargement of the spleen and liver, 
and dilation of the umbilical vein. 2,15 Immune hydrops occurs when pathological changes develop in the organs 
of the fetus and newborn because of this severe fetal anemia. Immune hydrops accounts for 13% of all causes of 
fetal hydrops. 16 The signs of immune hydrops vary with severity and may include fetal subcutaneous edema, 
effusion of fluid into body cavities, pulmonary hemorrhages, and enlargement of the fetal liver, spleen, and 
heart, as well as the placenta. Edema of the fetus and placenta can become significant enough for immune 
hydrops to be identifiable on prenatal ultrasound. 1,4 At birth, the newborn may demonstrate ascites, 
hepatomegaly, and splenomegaly. HDN and its consequences can lead to significant morbidity and mortality, 
and therefore, prevention of maternal sensitization is imperative. 
Rho (D) IMMUNE GLOBULIN 
RIG has been available in the United States since before 1970 and is widely used. Neonatal deaths and morbidity 
due to Rh sensitization have decreased dramatically since its introduction. According to the Center for Disease 
Control and Prevention, 17 the incidence of Rh HDN was 40.5 per 10,000 births in 1970. Today, the incidence has 
dropped to less than 5 cases per 10,000 births. This reduction is not completely attributable to RIG. The trends 
toward smaller family sizes and changing population demographics have also contributed to a natural decline in 
the incidence of Rh isoimmunization. 14 When antepartum or postpartum RIG are administered according to 
accepted guidelines, the rate of isoimmunization is reduced to approximately 0.1% 18 or approximately 1% of the 
natural risk. 19 Despite these marked improvements, neonatal morbidity and mortality due to Rh sensitization 
remain a clinical challenge. 
TESTING FOR FMH AND Rh ISOIMMUNIZATION 
Several maternal blood tests are used for identification and management of Rh negative women. The indirect 
Coombs, more commonly referred to as the antibody titer, is used to detect the presence and amount of anti-D 
antibody in the maternal circulation. Antibody screening is recommended during routine prenatal care and is 
especially important for the care of Rh negative women. If the antibody screen is negative, the woman has not 
been sensitized. However, if the indirect Coombs is positive, serial quantitative levels are drawn to detect and 
follow patterns of change. Laboratory variation exists with regard to titers, and therefore values that represent 
fetal risk are laboratory specific. 15 In general, titers of greater than 1:4 represent isoimmunization and titers 
exceeding 1:16 signal concern for the development of fetal hydrops, with risk increasing as titer values rise. 15 
Several tests are used to detect and quantify FMH. The most common of these is the Kleihauer-Betke (KB). The 
KB is used to estimate the presence and the amount of fetal RBCs in the maternal circulation following FMH. It 
was originally introduced to adjust the dosing of RIG. Currently, it is most commonly used to identify and 
quantify FMH. 20 The KB can detect even small amounts of RBCs that have crossed from the fetal intravascular 
compartment across the placenta through the intervillous spaces into the mother's circulation. 20 The formula is 
as follows: 
 
 
Fetal red cells=  maternal blood volume ×  maternal hematocrit ×  % fetal cells in KBTnewborn hematocrit  
The clinical use of KB is not without controversy and challenges. The American College of Obstetricians and 
Gynecologists (ACOG) recommends that the test be used in the management of all Rh negative 
women. 9 However, accuracy, sensitivity, and reliability problems exist. Therefore, the test is not routinely used 
in clinical practice. 15 In fact, KB tends to overestimate the dosage of RIG to be administered. 21 Further, the 
relationship of the findings to clinical management decisions and outcomes is not completely clear in the 
scientific literature. 22 A common use of KB is for the assessment and management of Rh negative women after 
motor vehicle accidents and other abdominal traumas. 9 
Other tests less commonly used to detect or quantify FMH are the erythrocyte rosette test, the enzyme-linked 
antiglobulin test, and flow cytometry. Each of these tests has different attributes and limitations. If any of these 
tests is positive on initial screen, the amount of the FMH is then estimated in order to determine the 
recommended dose of RIG. 21 
Case 1: S.T. 
S.T. is a 26-year-old G2P1 who presents for a follow-up appointment after her first prenatal visit because of a 
positive antibody titer. S.T. was seen for her first pregnancy when she was 18 years old and her complete 
medical record is available for review. Her blood type is Rh negative. Her antibody titer is positive to 1:4 
dilutions. S.T. states that she had many social problems during her first pregnancy and was “out of control” as a 
teenager. She had an antibody titer drawn at the initial prenatal visit at 34 weeks during her previous pregnancy 
that was negative. She did not have antepartum RIG because she failed to return for care. According to records, 
her first child was preterm and born by Cesarean for an abruption at 36 weeks gestational age. The baby spent 2 
days in the neonatal intensive care unit (NICU) for transition and observation. According to the surgical records, 
S.T. lost approximately 1200 mL of blood and had a postpartum hemoglobin of 8 g/dL and a hematocrit of 24%. 
She received the standard dose 300 μg of RIG on the second postoperative day and was discharged without 
infection, transfusion, or further complications. 
During the explanation of the laboratory findings with S.T., both she and her husband questioned how she could 
have been sensitized during her first pregnancy. Despite the marked success of RIG, postpartum-only 
administration has resulted in a failure rate of 1% to 2%. 15 In 1983, ACOG recommended routine antepartum 
RIG prophylaxis to Rh negative women at 28 weeks gestation for every pregnancy, including the first, to further 
reduce the development of antibodies. 4,9,10 The administration of 300 μg RIG at 28 weeks gestation, followed by 
postpartum administration of 300 μg within 72 hours of birth, was found highly effective in reducing the risk of 
Rh isoimmunization to 0.2%. 4,9,15 S.T.'s isoimmunization may represent this small RIG failure rate. 15 
Most current cases of isoimmunization are due to failure to administer RIG to appropriate candidates according 
to accepted guidelines following birth, elective or spontaneous abortion, amniocentesis, other potentially 
sensitizing events, or during the antepartum period. 9 Based on S.T.'s history, it appears that she had received 
the accepted RIG dosage during her postpartum hospitalization. Because of her lack of attendance at prenatal 
care, S.T. did not receive antepartum RIG. 
The lack of administration of antepartum RIG may have contributed to S.T.'s isoimmunization; however, a more 
plausible explanation appears to be the massive FMH that may have occurred at the time of her abruption, 
emergency cesarean, and immediate hemorrhage. The standard 300 μg dose of RIG that is administered to 
women for various reasons may be inadequate because the amount of FMH is rarely measured 
accurately. 7,23 The failure to identify and treat massive FMH is an ongoing clinical problem that leads to neonatal 
HDN. 2,8,21 Previously, it was recommended that KB be used for women considered at high risk for FMH, for 
example, those having abdominal trauma, abruption, placenta previa, multiple gestation, or manual removal of 
the placenta. However, this approach missed half of the large FMHs. Therefore, according to ACOG, 9 the 
American Association of Blood Banks currently recommends the use of KB for all Rh negative women who 
deliver Rh positive infants to estimate the amount of FMH and determine the amount of RIG that should be 
administered. However, the extent of use of this clinical protocol is unknown. Dosing of RIG is relatively 
standardized in the United States. In general, to prevent Rh isoimmunization, 10 μg of RIG is given for every 
milliliter of fetal blood that enters the maternal circulation. 4 Therefore, a mini dose of RIG (50 μg) covers 5 mL 
of D-positive fetal whole blood. Enough antibodies are contained in the standard 300 μg dose of RIG to prevent 
maternal sensitization of exposure up to roughly 30 mL of whole fetal blood or 15 mL of fetal cells 7,9 and will 
prevent most Rh negative women from becoming sensitized. If, however, the FMH is estimated to be more than 
30 mL, as may have been the case in S.T.'s situation, a second ampule of RIG can be 
administered. 15Theoretically, the dosage of RIG can be adjusted depending on the amount of exposure to Rh 
positive blood as calculated by KB. However, as noted, current dosage recommendations are fairly standardized 
based on sensitizing events 7 and KB is not always used to determine RIG dosing. 
S.T. was isoimmunized but with a titer of 1:4 there was a low risk of fetal effects. She also lacked a history of an 
affected fetus or neonate by Rh sensitization. 9 S.T. was followed with repeat antibody titers at 20 weeks and 
then at 2- to 4-week intervals throughout the pregnancy. 2 In the case of S.T., her 20, 24, and 28 week titers 
remained 1:4 until 32 weeks when they rose to 1:8. However, since the levels stabilized at 1:8, amniocentesis 
was not required. S.T. delivered without complications at 38 weeks. Because S.T. was already isoimmunized, she 
did not receive antepartum or postpartum RIG. 
The management of an Rh-sensitized woman during pregnancy is one that requires ongoing surveillance of the 
mother and fetus. The next case will explore the comprehensive management plan for a more seriously 
isoimmunized woman. Women with antibody titers greater than 1:8 generally require close surveillance, 4 but 
when serial titers rise to the level of 1:16 to 1:32 by indirect Coombs test, interventions such as nonstress testing 
and amniocentesis would generally be indicated. 2,15 Perinatal nurses often participate in the coordination and 
planning of care for sensitized women as part of collaborative practice within the perinatal team. 
Case 2: V.S. 
V.S. is a 36-year-old Caucasian G7P5015 who is 12 weeks pregnant and presenting for prenatal care. V.S. was 
identified as Rh negative and had received antepartum and postpartum RIG during each of her 5 full-term 
pregnancies. During a missionary trip to China 2 years ago she experienced a spontaneous abortion. She did not 
receive health care because she was in a remote village. She estimated that she was 14 weeks pregnant at the 
time of her loss and did not receive RIG. At V.S.'s initial prenatal visit her indirect Coombs was positive with an 
antibody titer of 1:8 for anti-D. In this case, the second trimester loss probably caused an FMH that led to 
isoimmunization. Although V.S. generally avoided intervention in her previous pregnancies, both she and her 
husband wanted to do everything possible to maximize the health of their developing infant. 
V.S. had an ultrasound at 18 weeks to confirm gestational age and to survey anatomy because of V.S.'s advanced 
maternal age. The plan of care included, in addition to serial antibody titers, serial ultrasounds to observe for 
characteristics of fetal hydrops that can be identified using this technology. However, the relationship between 
these findings and the severity of hemolytic disease or fetal hydrops has not been demonstrated conclusively by 
research. 2 Doppler flow studies, examining mainly the middle cerebral artery, are also sometimes used. These 
flow studies have been researched extensively and are being used to manage the prenatal care of women 
whose pregnancies are complicated. 4Unfortunately, there is overlap in Doppler flow values for the normal fetus 
and the severely affected fetus of a sensitized mother. 2 However, the technology of ultrasound and Doppler 
flow studies is advancing rapidly and may soon be more useful in diagnosing the degree of fetal anemia. 
Initially V.S.'s antibody titers remained stable at 1:8 and, fortunately, her fetus did not demonstrate signs of fetal 
hydrops at the 18, 22, or 24 week ultrasounds, where average growth was also noted. However, at 26 weeks 
gestation, V.S.'s antibody titers rose to 1:16. A decision was made to immediately proceed with an 
amniocentesis in order to perform an amniotic fluid spectrophotometric measurement for bilirubin 
levels. 2,15 The perinatal nurse counseled V.S. and provided support during the procedure. The amniocentesis 
was performed under sterile conditions and was guided by ultrasound. Further, the fetus was reevaluated for 
signs of immune fetal hydrops at the time of the procedure. 4 
The amniotic fluid appeared light yellow in color. The optical density of the amniotic fluid was measured using 
the Liley technique 4 to determine the fetal risk of erythroblastosis fetalis. Maternal-fetal management is based 
on a plot of the optical density of the amniotic fluid to determine the Liley zone. Fetal risk is 95% predictable 
based on the Liley zone and therefore this information can guide management decisions. With worsening 
disease and rising bilirubin levels in the amniotic fluid, the severity of fetal compromise increases, as measured 
in zones of the Liley Graph: 
o Zone I – unaffected fetus or mildly affected fetus 
o Zone II – fetus with mild to severe anemia, prognosis is fair but includes risk of stillbirth 
o Zone III – severe anemia, fetal death could occur within 7 to 10 days if not transfused or delivered. 2,4 
Because V.S.'s amniotic fluid results were rated in the lower part of Zone II, a plan was made to repeat an 
amniocentesis every 2 to 4 weeks. Repeated measures using the Liley method are more reliable in assessing 
fetal condition than is a single measure. 15 If the values rise higher into Zone II or into Zone III, especially prior to 
30 weeks, further interventions are needed. 
V.S. began antenatal testing at 32 weeks with biweekly nonstress tests (NSTs) and weekly biophysical profiles 
(BPPs) that are generally recommended in the literature. 9,24 A nonreactive NST was observed. The fetal monitor 
tracing was scrutinized for patterns associated with fetal anemia, chiefly a nonreactive tracing, or one that 
includes late decelerations (Fig 2), or that demonstrates a sinusoidal rhythm (Fig 3). 
 
Fig 2 Persistent late decelerations associated with a severely compromised fetus. Reprinted with 
permission from reference25. 
 
 Fig 3 The sinusoidal heart rate pattern associated with severe fetal anemia. Reprinted with permission 
from reference26. 
 
These patterns also may indicate the absence of autonomic nervous system control of cardiac function, heart 
failure, or hypoxia. 6 For V.S. there were no accelerations of fetal heart tones on the NST but there were also no 
late decelerations or sinusoidal pattern. 27A BPP was conducted and the result was 8/10. 28 Therefore, V.S. was 
sent home with follow-up appointments for biweekly antenatal testing. 
At 33 weeks V.S. reported decreased fetal movement. Once again her NST was nonreactive, and the BPP was 
4/10. The physician made a decision to perform an immediate amniocentesis under ultrasound to evaluate the 
amniotic fluid and to simultaneously visually screen for characteristics of immune fetal hydrops. A fetus that is ill 
enough to demonstrate hydrops on ultrasound examination will generally have a hematocrit of less than 
15% 2 although specific values indicating the need for intervention are controversial. V.S.'s fetus had no signs of 
hydrops but had moved higher into Liley Zone II. It was determined that there was a need for immediate 
intrauterine fetal transfusion (IUFT). The goal of IUFT is to correct the anemia and improve fetal oxygenation, 
therefore improving the health of the developing fetus. IUFT intravascularly has a fetal survival rate of greater 
than 90%. IUFT can be performed intravascularly, intraperitoneally, or the 2 methods may be 
combined. 24 Although invasive and not without risk, IUFT is an essential intervention that has improved the 
health of infants with erythroblastosis fetalis. In general, intravascular transfusion is the preferred method, 
unless it is technically impossible. 15 
The perinatal nurse has an important role in IUFT. These responsibilities include carefully monitoring both the 
mother and the fetus before, during, and after the procedure, and obtaining the fresh, irradiated, 
cytomegalovirus-negative, group O, Rh negative blood, cross-matched against maternal serum, that needs to be 
available. 29 During an intrauterine transfusion, blood is infused and removed in small amounts through a vein or 
artery. IUFT was repeated every 2 weeks in this case to avoid fetal hydrops 2 until 36 weeks gestation. A decision 
was made to induce V.S.'s labor 2 weeks later at 38 weeks. 4,15,30 
Fetuses that are severely affected by erythroblastosis fetalis are at risk for intrauterine fetal death. Since the 
1960s, preterm induction of labor dramatically decreased the incidence of perinatal deaths due to HDN. 31 Prior 
to the use of IUFT, preterm delivery was the only management option for the care of affected fetuses. The use 
of IUFT has helped to prolong pregnancy and, coupled with improvements in neonatal care, survival has 
dramatically improved. 15 
The optimal gestational age for delivery is somewhat controversial 15 but delivery prior to 32 weeks is not 
recommended. 24 The decision for delivery of a sensitized woman carrying an affected fetus is based on several 
factors including the gestational age, lecithin-sphingomyelin (L-S) ratio, presence or absence of 
phosphatidylglycerol (PG), the severity of fetal anemia, and the presence of immune hydrops. 24 The ultimate 
decision of timing of delivery would be by the perinatal team managing the sensitized woman. 24 For example, in 
cases of mild hemolysis, induction of labor is generally recommended at 37 to 38 weeks unless lung maturity has 
been documented earlier. If the Liley Zone falls into the severe range (III), the amniotic fluid can be analyzed for 
fetal lung maturity to help determine optimal timing for delivery. The risks of preterm delivery are weighed 
against the benefits. When the fetus is severely affected early in the third trimester, the last transfusion may be 
timed for 30 to 32 weeks, with delivery planned for 32 to 34 weeks to maximize fetal survival and lung maturity. 
Fetal lung maturation is not accelerated nor suppressed by HDN. 15 Therefore, if the fetus is delivered 
prematurely, steroids can be administered to the mother to hasten fetal lung maturity. 4 Induction of labor with 
an unfavorable cervix increases the risk of cesarean delivery. Therefore if the cervix is not favorable (Bishop's 
score <8), cervical ripening is recommended prior to induction. 4,15,32 
A tertiary care facility that includes a NICU is the optimal intrapartum setting. The sensitized woman is 
considered high risk and therefore continuous electronic fetal monitoring during labor is recommended with use 
of an internal fetal scalp electrode as soon as is feasible. 15 This affords the opportunity to recognize fetal heart 
rate patterns that may indicate fetal compromise. The fetus should be observed closely for a sinusoidal rhythm 
or persistent late decelerations during labor. Figures 2 and 3 represent examples of these patterns. 
If either of these fetal heart rate patterns occur, appropriate nursing interventions are needed to maximize fetal 
oxygenation and recognition of the need for further intervention. 33 Operative delivery may be indicated to 
accelerate the birth if fetal labor intolerance or fetal compromise are suspected. 15 In cases of fetal hydrops, 
labor dystocia and birth trauma is also a crucial consideration. Conservative management of labor may be 
appropriate because of the possibility of the larger abdominal circumference of hydropic infants. If the labor is 
prolonged, intervention by Cesarean may be required. Severely affected neonates will benefit from the care of a 
multidisciplinary neonatal resuscitation team. 34 Following birth the umbilical cord should be clamped without 
delay. 15 Fetal cord blood is drawn routinely at delivery for Rh and direct Coombs. 
The perinatal team met with V.S. and her husband and decided to perform the last IUFT at 36 weeks and induce 
labor at 38 weeks. V.S. was admitted and her Bishop Score was only 4. She was given prostaglandins vaginally for 
cervical ripening, followed by pitocin induction. She was carefully monitored during labor in the tertiary care 
center and delivered a 7-lb 4-oz viable male infant. Because of the careful antepartum management the infant 
did not experience fetal hydrops, and the birth was relatively uneventful. 
There is dramatic variation among infants born to sensitized mothers, depending on the nature of the maternal 
immune response and degree of fetal anemia. 29 Anemic neonates born to sensitized mothers require special 
care. A severely affected live-born infant will appear pale, edematous, and limp, and require immediate 
neonatal resuscitation. 
The multidisciplinary health care team caring for a severely affected fetus that has failed to respond to 
intrauterine therapy will need to be prepared for complex neonatal resuscitation. The hydropic newborn may 
need high frequency ventilation and the placement of chest tubes to ensure adequate ventilation. 34 This infant 
may also need umbilical-artery and umbilical-vein lines to aid in resuscitation. 35 In addition to these measures, 
the hydropic infant may need blood products, albumin, and/or diuretics to maintain intravascular volume. The 
newborn may also require the administration of sodium bicarbonate, 1 to 2 mEq/kg, to reverse acidosis. In 
addition, blood sugar monitoring is necessary because of the possibility of hyperinsulinism and hypertrophy of 
the pancreatic islet cells. 29 Following stabilization after birth, transportation to the NICU is indicated. 
The newborn's cord blood hemoglobin, reticulocyte count, and serum unconjugated bilirubin should be 
measured to determine the need for exchange transfusion. 36 The decision to perform an exchange transfusion 
is determined by the degree of risk for rapid development of severe anemia and/or hyperbilirubinemia. An 
exchange transfusion is done to increase the RBC count and decrease the levels of circulating bilirubin. The cord 
blood hemoglobin and serum bilirubin levels will guide the management. Hemoglobin concentrations of less 
than 13 g/dL or serum bilirubin concentrations of greater than 4 mg/dL indicates the need for exchange 
transfusion. 36 Infants who have received IUFT rarely require neonatal exchange transfusion. However, blood 
transfusions are commonly used to manage severely affected anemic infants. 24 
Jaundice may be absent at birth but evident within a few hours, particularly for anemic neonates. Before 
treating the infant, a Coombs test should be obtained. The direct Coombs test is generally positive in affected 
infants who also are severely anemic. Direct and indirect bilirubin levels will also need to be monitored closely. 
Jaundice should be managed aggressively with transfusions and phototherapy. If the levels of bilirubin rapidly 
increase, the infant is at risk for kernicterus. 1 Untreated kernicterus can damage the newborn's central nervous 
system, especially in a preterm infant. An infant who survives kernicterus may develop spasticity, muscular 
incoordination, and the possibility of mental retardation. 1 Therefore, prompt identification of and intervention 
for severe jaundice within the first 12 hours following birth is an essential component of nursing care. 
A NICU nurse evaluated V.S.'s infant in the birthing room. V.S.'s infant's cord blood hemoglobin was greater than 
13 g/dL and the bilirubin was less than 4 mg/dL; therefore, exchange transfusion was not initially necessary. 
Since the baby was stable and not experiencing any difficulty, he was given to the mother for bonding and 
breastfeeding. After birth, bilirubin levels were followed serially to guide the management decisions regarding 
the need for transfusion. 24,36 Serum bilirubin levels need to be monitored closely until they begin to fall. 29 V.S's 
baby did become jaundiced within 12 hours of birth and was managed with phototherapy and 2 
transfusions. 30 The infant was discharged at 4 days of age. After discharge, weekly hematocrit and reticulocyte 
levels were checked for 8 weeks. 24 If anemia had persisted, additional blood transfusions would have been 
required. 34 
With appropriate perinatal and neonatal management, the pregnancy outcome was good. The pregnancy 
became much more technological than S.V. desired but she understood this was essential to the infant's 
survival. She did not receive postpartum RIG because she was already isoimmunized. Following more discussion 
with the perinatal team, S.V. chose to have a postpartum tubal ligation. If S.V. had received RIG following her 
second trimester pregnancy loss, these complications may have been prevented. 37 
Case 3: W.W. 
The last case will explore the nursing implications of RIG administration. W.W. is a 24-year-old G1P0. She is 
Caucasian and her husband is Asian. She presented for her initial prenatal visit at 8 weeks. On the initial prenatal 
laboratory testing it was determined that W.W. is Rh negative and had a negative antibody screen. Since that 
time W.W. has searched the internet and found some sources that questioned the safety and necessity of 
antepartum RIG. W.W. is now at 28 weeks gestation and is asking the perinatal nurse educator many questions 
about the efficacy, safety, and necessity of antepartum RIG. She stated that she is aware that RIG is derived from 
blood products and she questions the need for the injection. 
The percentage of Rh negative individuals varies based on ethnicity. For example, Rh negative individuals 
account for approximately 13% of Caucasians, 7% to 8% of African Americans, and less than 1% of Native 
Americans, Inuit peoples, and members of Asian groups. 13 Because W.W.'s husband is Asian, there is a greater 
than 99% chance that he is Rh positive. Without knowing the blood type of the father, an Rh negative woman 
has as high as a two-thirds chance of becoming pregnant with an Rh positive baby. 4 
If paternity is certain and the father of the baby is known to be D-negative, the pregnant woman can be 
counseled to decline antepartum RIG administration. 4,9 If the father is heterozygous for Rh, the baby has a 50% 
chance of being Rh positive. The only way to determine if the father is heterozygous would be to know if he has 
fathered any other Rh negative children or had a genotype analysis. However, routine genetic analysis is not 
cost-effective and therefore is not recommended for use in determining whether RIG should be 
administered. 2 Therefore, if the father's blood type is not known, the paternity is uncertain, or the father is Rh 
positive and the mother is Rh negative, RIG should be given. Alternatively, amniocentesis can be offered to the 
woman, because testing is available to determine the fetal genotype. 2,4 If the fetus is Rh negative, no further 
interventions are required. In the future, advances in genetic testing may allow selective administration to only 
the necessary candidates. 
Informed consent with written documentation is a nursing consideration for the administration of RIG. While 
RIG is generally considered safe, no drug is risk free. Informed consent should include several different 
considerations related to administration of the drug, including possible risks. Some prenatal clients will refuse 
RIG administration. Counseling regarding the increased risk of prenatal sensitization and documentation of this 
discussion in the prenatal record are recommended. 2,38 RIG administration is based on well-designed cohort or 
case-controlled trials, rather than on randomized controlled trials. This means that antepartum RIG should be 
routinely provided to eligible candidates and that there is at least fair evidence that benefits outweigh the 
risks. 12,37 
Despite its success, RIG administration is somewhat controversial. Immune globulin is a blood product derived 
from human plasma. This may be of particular significance for women who hold religious beliefs that prohibit 
the use of blood products. The issue of clients who refuse blood products for religious reasons has not been 
addressed in the literature. During the preparation process, human plasma is screened for viruses as prescribed 
by the Food and Drug Administration. 4 There is a small risk of contracting a pathogen that is currently unknown 
and thus not included in the current screening protocol, but decades of experience with its administration have 
not demonstrated any deleterious effects. 37 This controversy may eventually be resolved by research that is 
underway using monoclonal antibody techniques to reproduce human anti-D antibody. 4 If this work is 
successful, the risks of exposure to impurities in the human blood supply will be completely eliminated. 
Another concern is that until 2001, Thimerosal 19 was used as the preservative in RIG. A recent modification in 
RIG preparation has eliminated this problem. Thimerosal is a mercury derivative used as a preservative to which 
certain individuals who are sensitive may possibly experience potentially serious allergic reactions and potential 
neurologic damage to the fetus. This had raised questions from clients concerned about immunization 
preservatives. A number of companies market RIG. According to the Ortho Company that manufactures 
RhoGAM™ RIG, Thimerosol-containing syringes would have reached their expiration date by April 2003. 19 Since 
Thimerosal is no longer used as the preservative, concerns about its inclusion in RIG are no longer warranted. 
In this case, the perinatal nurse counseled W.W. about antepartum RIG. W.W. was reluctant to accept the 
injection. Therefore, the nurse suggested that W.W.'s husband have a blood group and typing done. W.W. 
agreed that if her husband was Rh positive she would proceed with antenatal RIG. W.W.'s husband was found to 
be Rh positive and therefore, she agreed to receive an antepartum RIG injection at 28 weeks. The administration 
of RIG is a major preventative health strategy that can improve perinatal outcomes. 9,13 
RIG should remain refrigerated but not frozen prior to administration. The RIG syringe should be inspected for 
clarity. A cloudy appearance or the presence of particulate matter would be an indication of potential 
contamination. 19,39 The route of administration of RIG is also critical. To prevent Rh isoimmunization during or 
following pregnancy, the injection should be given intramuscularly, not intravenously. The deltoid muscle may 
be preferable to the gluteal muscle. 40 If the injection is given in the gluteal region it may only reach the 
subcutaneous tissue and absorption will be delayed. 40 According to the package insert, 19,39 women should be 
observed for 20 minutes following injection to detect any possible allergic reaction although they are rare. 
Lastly, a woman should be informed about potential side effects that most commonly include local 
inflammation, malaise, chills, rashes, and in rare instances anaphylaxis. 19,39 Special consideration should be 
given if a woman has had past allergic reactions to any human immune globulin such as immunoglobulin A or 
has an immune deficiency. If a woman reacts to one dose of RIG, consultation with an immunologist is advisable 
prior to any future administration of RIG to the same woman. 39 
In order to identify a woman's risk for isoimmunization, a blood type, Rh, and antibody screen should be drawn 
at the first prenatal visit. This also identifies sensitization early if it has already occurred. Repeat antibody 
screening at 28 weeks is controversial. The rationale for repeat screening is to determine if sensitization has 
occurred since the initial antepartum Coombs test, so that care can be managed appropriately. 4 However, the 
likelihood of that is less than 0.18%. 23 Although the American Association of Blood Banks recommends repeat 
testing, ACOG recommends that the decision be individualized. 9There is no rationale for having the woman wait 
for a negative antibody screen result prior to RIG administration. 
Optimally, RIG should be administered at approximately 28 weeks gestation and within 72 hours of a sensitizing 
event. If the injection was not given within 72 hours because of an error, it still should be administered as soon 
as possible to provide some benefit. The half-life of RIG is 24 days. 9 The findings of one study showed that 
administration provided protection even when given within 9 to 10 days 39 and other authors indicated that it 
can provide some benefit if given up to 28 days after delivery. 8,15 If delivery occurs within 3 weeks of an 
antepartum injection of a standard 300 μg dose, the postpartum dose of RIG may be held 9 unless massive FMH 
is suspected. Further, women who had not delivered 12 weeks after the administration of antepartum RIG 
should receive a second dose. 15The administration of one 300 μg antepartum dose of RIG will not result in a 
positive direct Coombs of the baby. Further, the use of antepartum RIG is not associated with adverse fetal 
outcomes. 37 If a mother is already Rh sensitized, RIG cannot prevent damage to an Rh positive fetus, and 
therefore it should not be administered. 41 However, if there is any doubt about maternal sensitization, RIG 
should be administered. 9 
NURSING IMPLICATIONS 
As members of the multidisciplinary health care team, nurses share responsibility for early detection and 
identification, patient education, proper management, and follow-up of the mother and infant. 2 Perinatal 
nurses often coordinate the care of sensitized women prenatally, including antenatal testing, as well as during 
the intrapartum and postpartum periods. Neonatal nurses care for infants born with erythroblastosis fetalis, 
immune hydrops, and/or severe anemia. 
For perinatal nurses involved in antenatal care, it is crucial for the nurse to obtain a complete, detailed 
obstetrical history at the initial prenatal visit. This is especially true when women have transferred prenatal care 
from one setting to another. A mother who has experienced fetal HDN is likely to experience a more severe 
anemia in subsequent pregnancies with Rh positive infants. 4 Continuity of care and careful record-keeping are 
imperative for Rh negative women at risk for Rh isoimmunization. 
Perinatal nurses often interact with pregnant women for history-taking and education before any laboratory 
testing is completed or results known. 2 In fact, nurses often send women for ordered laboratory testing, 
including antibody screening, and thus they are in important positions to educate and explain the reasons for 
testing. If an antibody screen is positive prenatally, early diagnosis and referral to the appropriate perinatal care 
providers is essential. In these situations, continued interactions with the perinatal nurse can assure holistic care 
of the family that is experiencing an at-risk pregnancy. Frequent visits for follow-up of Rh sensitization include 
opportunities to interact with the perinatal nurse for further education, counseling, and support. 
Additionally, the administration of RIG is most often a nursing responsibility. Nurses provide education about 
RIG and an identification card for the woman indicating that she is Rh negative. Further, nurses contribute to 
women's understanding of the blood work and other testing that is done, including the determination of the 
need for postpartum RIG administration. Documentation of the nursing care and education provided is 
essential. 2 
Finally, neonatal nurses are responsible for knowing the mother's history and caring for the infant who may be 
critically ill. Nurses not only provide intensive care and follow-up for the newborn, but also educate and support 
the parents. The scientific literature contains reassuring longitudinal outcome data that nurses can share with 
parents. For example, studies of long-term outcomes for children who were treated with IUFT demonstrated 
favorable neurologic development. 42,43 Parents may experiences a variety of emotions, including fear and guilt, 
and they benefit from the support and guidance of the nursing staff. Fostering continuity of care for the families 
of critically ill infants can be helpful. 
In summary, perinatal and neonatal nurses have significant roles in the prevention, identification, assessment, 
and care of women, fetuses, and infants at risk for Rh isoimmunization problems. Nurses can help to prevent 
negative sequelae by contributing to surveillance and collaborating with physicians as a part of the 
multidisciplinary perinatal health care team. Once sensitization is identified, perinatal and neonatal nurses can 
positively impact the care of high-risk pregnancies and neonates. 
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CE TEST QUESTIONS 
General Purpose: To provide registered professional nurses with information on the controversies and 
challenges surrounding the administration of Rho (D) immune globulin (RIG) prenatally and during the 
postpartum period. 
Learning Objectives: After reading this article and taking this test, you will be able to: 
1. Discuss the development of Rh isoimmunization. 
2. Explain the etiology and presentation of hemolytic disease of the newborn. 
3. Outline the prevention and management of Rh isoimmunization. 
1. Rh isoimmunization is the process of 
a. maternal antibody formation. 
b. feto-maternal hemorrhage. 
c. co-mingling of fetal and maternal blood. 
d. vascular exchange within the placenta. 
2. Rh isoimmunization most often occurs 
a. during the first trimester of pregnancy. 
b. during the second trimester of pregnancy. 
c. during the third trimester of pregnancy. 
d. at the time of birth. 
3. Most feto-maternal hemorrhages 
a. involve less than 0.1 mL of fetal blood mixing with maternal blood. 
b. occur in the 12th week of gestation. 
c. involve 30 mL or more of fetal blood mixing with maternal blood. 
d. result in significant fetal morbidity or mortality. 
4. Hemolytic disease of the newborn (HDN) develops 
a. immediately after Rh isoimmunization. 
b. as a result of erythroblastosis fetalis. 
c. 24 to 48 hours after delivery. 
d. only during a first pregnancy. 
5. A warning sign of HDN is 
a. ascites. 
b. constriction of the umbilical vein. 
c. oligohydramnios. 
d. placental thinning. 
6. A sign of immune hydrops is 
a. hydrocephaly. 
b. hepatosplenomegaly. 
c. hypoplastic left heart syndrome. 
d. placental insufficiency. 
7. Primarily due to the availability and use of Rho (D) immune globulin (RIG), the incidence of Rh hemolytic 
disease of the newborn is now 
a. 10.5 per 10,000 births. 
b. fewer than five per 10,000 births. 
c. about 20 per 10,000 births. 
d. 40.5 per 10,000 births. 
8. The fetus is considered at risk for developing fetal hydrops if a pregnant woman's anti-D antibody titer is 
greater than 
a. 1:2. 
b. 1:4. 
c. 1:10. 
d. 1:16. 
9. The test most often used to determine the amount of fetal blood that has entered the maternal circulation is 
the 
a. indirect Coombs. 
b. erythrocyte rosette test. 
c. Kleihauer-Betke stain. 
d. enzyme-linked antiglobulin test. 
10. The common method of quantifying fetal blood in the maternal circulation 
a. has not been used to determine the appropriate RIG dose. 
b. tends to underestimate the amount of RIG required. 
c. is extremely accurate in identifying the appropriate RIG dose. 
d. tends to overestimate the amount of RIG required. 
11. The most highly effective method of reducing the incidence of Rh hemolytic disease of the newborn is to 
administer RIG to Rh negative women 
a. in the postpartum period following the first delivery only. 
b. in the postpartum period following every delivery. 
c. in the antepartum period of every pregnancy. 
d. in the antepartum and postpartum periods of every pregnancy. 
12. A likely explanation for RH isosensitization in a woman who had received standard dosing of RIG at the 
appropriate time would be 
a. failure to do an anti-D antibody titer. 
b. a massive feto-maternal hemorrhage. 
c. placenta previa. 
d. severe pregnancy-induced hypertension. 
13. Delivery is warranted within seven to 10 days if amniocentesis reveals 
a. Liley zone I. 
b. Liley zone II. 
c. Liley zone III. 
d. bilirubin in the amniotic fluid. 
14. Which of the following fetal heart monitoring findings indicates fetal anemia? 
a. a sinusoidal rhythm 
b. a reactive nonstress test pattern 
c. increased variability 
d. early decelerations 
15. The method of choice for treating erythroblastosis fetalis is 
a. immediate delivery. 
b. neonatal exchange transfusion. 
c. administration of high-dose RIG. 
d. intrauterine fetal transfusion. 
16. A subsequent pregnancy with an Rh-positive infant in a woman who has already experienced fetal HDN is 
most likely to result in 
a. an unaffected fetus. 
b. a milder case of HDN. 
c. a more severe anemia. 
d. premature delivery. 
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